By Lizzy Lovinger and Mark Harrington This November’s U.S. election provides an opportunity for activists to pause and assess our approach to policy. We face some unprecedented roadblocks on our path to end HIV, hepatitis C virus (HCV), and tuberculosis…
By Mike Frick and Gisa Dang Background Two years into the COVID-19 pandemic, governments embarked on a journey to create a Pandemic Agreement, negotiated among member states of the World Health Organization (WHO), that would establish binding rules on how…
By Joelle Dountio Ofimboudem The hepatitis C Virus (HCV) remains one of the deadliest infectious diseases, despite the existence of an effective eight- to-twelve week cure. Still, of the 50 million people estimated to be living with HCV worldwide, 36…
By Wilson Kutamba and Richard Musisi With an estimated TB incidence of 200 cases per 100,000, Uganda is one of the 30 countries with the highest burden of TB/HIV globally. For the estimated 86,000 people living here who fell ill…
By De'Ashia Lee Among women aged 24–35, Black women were the only U.S. demographic for which HIV disease was a leading cause of death in 2021. 1 This alarming health disparity is the end result of a culture of oppression and…
As we approach the end of 2024, we want to share with you some of the remarkable progress we’ve made together, and you'll see some of our work in the 2024 TAG Update.
The Community Research Advisors Group (CRAG) celebrates both the findings and the methodology of Study 35, a phase I/II clinical trial of the tuberculosis (TB) preventive treatment regimen known as 3HP in children.
In advance of the 52nd Meeting of the Board of the Global Fund to Fight AIDS, Tuberculosis, and Malaria (the Global Fund) and the 2024 Union World Conference on Lung Health, Treatment Action Group (TAG) releases this statement in response to ongoing conversations about the Global Fund’s program allocations for HIV, tuberculosis (TB), and malaria.
Treatment Action Group (TAG) is deeply concerned by the reported decrease in domestic funding for tuberculosis (TB) services announced today in the World Health Organization's 2024 Global Tuberculosis Report.
TAG recognizes Gilead Science’s announcement that it has issued six voluntary licenses to produce generic lenacapavir for distribution within 120 high HIV burden countries as a first step toward broadening access to this potent preventive drug for millions of people at risk of HIV.